share_log

HC Wainwright & Co. Reiterates Neutral on Lyra Therapeutics, Maintains $2 Price Target

Benzinga ·  Mar 14 10:54

HC Wainwright & Co. analyst Matthew Caufield reiterates Lyra Therapeutics (NASDAQ:LYRA) with a Neutral and maintains $2 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 314

Recommended

Write a comment